Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_3
3
38%
Ph phase_1
2
25%
Ph phase_2
3
38%

Phase Distribution

2

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(4)
Terminated(2)
Other(2)

Detailed Status

Completed4
unknown2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 23 (37.5%)
Phase 33 (37.5%)

Trials by Status

terminated113%
unknown225%
completed450%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects

NCT06625710
completedphase_2

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH

NCT02855892
withdrawnphase_2

GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

NCT03959553
unknownphase_3

A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients

NCT02854072
completedphase_1

Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma

NCT01247623
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06625710Phase 1

Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects

Completed
NCT02855892Phase 2

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH

Completed
NCT03959553Phase 2

GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

Withdrawn
NCT02854072Phase 3

A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients

Unknown
NCT01247623Phase 1

Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma

Completed
NCT01579188Phase 3

Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer

Unknown
NCT00444782Phase 2

A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.

Completed
NCT00358566Phase 3

GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8